A novel mutation of WFS1 gene in a Chinese patient with Wolfram syndrome: a case report

Min Li†, Jia Liu†, Huan Yi†, Li Xu†, Xiufeng Zhong‡* and Fuhua Peng†*

Abstract

Background: Wolfram syndrome (WS), caused by mutations of the Wolfram syndrome 1 (WFS1) gene on chromosome 4p16.1, is an autosomal recessive disorder characterized by diabetes insipidus (DI), neuro-psychiatric disorders, hearing deficit, and urinary tract anomalies.

Case presentation: Here we report a 11-year-old Chinese boy who presented with visual loss, was suspected with optic neuritis (ON) or neuromyelitis optica (NMO) and referred to our department for further diagnosis. Finally he was diagnosed with WS because of diabetes mellitus (DM) and optic atrophy (OA). Eight exons and flanking introns of WFS1 gene were analyzed by sequencing. A novel mutation c.1760G > A in WFS1 gene of exon 8 was identified.

Conclusion: This report reviews a case of WS associated with a novel mutation, c.1760G > A in WFS1 gene of exon 8, and emphasizes that WS should be taken into account for juveniles with visual loss and diabetes mellitus.

Keywords: Wolfram syndrome, WFS1 gene, Mutation

Background

Wolfram syndrome (WS) is a rare autosomal recessive disorder, mainly associated with juvenile-onset type 1 diabetes mellitus (T1DM) and optic atrophy (OA). Diabetes insipidus (DI), neuro-psychiatric disorders, hearing deficit, and urinary tract anomalies develop in many patients [1, 2].

Mutations of the WFS1 gene on chromosome 4p16.1 are in charge of the clinical manifestations in majority of patients with WS [3, 4]. WFS1 gene encodes wolframin, an 890-amino acid glycoprotein localized primarily in the endoplasmic reticulum (ER) [5]. Genetic analyses in WS have identified a wide spectrum of mutations, including missense, frame shifting, nonsense, and splicing mutations, predominantly located in exon 8 (80–90%) [6].

Here we report a WS case onset with OA and T1DM in a Chinese juvenile. A novel mutation c.1760G > A in WFS1 gene of exon 8 was found, which was never reported before.

Case presentation

A 11-year-old boy was admitted to our department with a 1-year history of progressive visual loss. He was initially taken as pseudomyopia without treatment. Four months ago, he was diagnosed with T1DM and found bilateral OA by brain magnetic resonance image (MRI), optic coherence tomography (OCT) and visual evoked potential (VEP) (no pictures provided) in the local hospital. And he was treated with compound anisodine hydrobromide injection and mouse nerve factor injection for one and a half months without alleviating. Then the boy was referred to our department with suspicious of ON or NMO.

The patient was hospitalized in local hospital because of a sudden faint in school 4 months ago. Some of his laboratory tests were as follows: finger point blood glucose test > 33.3 mmol/L, blood glucose 38 mmol/L, HbAc 15.8%, and positive urine sugar and ketone. His mother recalled that he was polydipsia, polyphagia and polyuria with weight loss for 1 month. So he was diagnosed with ‘type 1 diabetes mellitus (DM1), ketoacidosis and coma,’ and treated with insulin pump of Medtronic in the local hospital.

Some of his main investigations in our hospital revealed as follows. ANA+ENA+ANCA, TSH in serum, AQP4 and OCB in serum and cerebrospinal fluid were...
negative. His HbAc was 5.9% and blood glucose was 4.88 mmol/L. His anti-GAD antibody and anti-insulin antibody in serum was negative. Regular urinalysis and hearing was normal. The photographic images of the patient’s eyes showed bilateral papillary atrophy (Fig. 1). OCT measure around the disc showed thin retina (Fig. 2). Brain MRI showed bilateral optic nerve atrophy thinner (Fig. 3). OA and DM1 in a young patient suggested his clinically diagnose of WS.

The patient was the first child, and had one little sister. Both his little sister and his parents had no signs or symptoms. And his parents were non-consanguineous.

For further confirmation of the diagnosis, we got the consent to sequence WFS1 gene for the patient and his parents without his other family members. The patient’s number 587 codon, c.1760G > A, located in exon 8, mutated and changed from arginine to glutamine. He was homozygote while his parents were both heterozygote of mutant genes. We used the Human Gene Mutation Database (HGMD) to assess that this was a novel mutation. Exome sequencing disclosed a novel mutation in WFS1 gene (the novel variant c.1760G > A) (Fig. 4), confirming WS.

Discussion and conclusions

WS is a rare progressive neurodegenerative hereditary disease, known as DI-DM-OA-D which stands for diabetes insipidus, diabetes mellitus, optic atrophy, and deafness [1]. The coexistence of T1DM and OA in juvenile suggests WS but molecular confirmation is mandatory [7]. Patients usually present with DM followed by OA in the first decade. DM is often the first clinical sign of WS, but differ from classical T1DM in normal autoimmune laboratory parameters. Patients with WS usually demonstrate progressive ophthalmologic symptoms. Deafness in WS is commonly a high frequency, symmetric hearing loss, usually detected in the second or third decade with a relatively slow rate of deterioration [8, 9]. Some studies have reported urological abnormalities which were expected about 58% in patients with WS [10].

Studies showed that WS was caused by loss-of-function mutations in the WFS1 gene, encoding wolframin [6]. Wolframin is abundantly expressed in pancreas, brain, heart, and muscle, with lesser amounts being present in liver and kidneys [11]. Although no function has yet been attributed to wolframin. Recently, it has been shown that WFS1 gene has a crucial role in the negative regulation of a feedback loop of the ER stress signaling network and preventing secretory cells. For example, wolframin deficiency in mice leads to progressive loss of B cells and impaired glucose tolerance [12]. Yamamoto H et al. concluded that dual dysfunction of wolframin in optic nerve glial cells and retinal ganglion cells in the cynomolgus monkey might explain the progressive optic nerve atrophy in WS [13].
The prognosis of WS is currently poor as most patients die at the age of 30s (range, 25–49 years) because of respiratory failure as a result of brain stem atrophy [1, 10]. But our case demonstrates an unusual presentation. The boy reported here onset with OA and T1DM, and both deafness and urological abnormalities were not found. His parents were non-consanguineous and were found mutant heterozygote while he was mutant homozygote. His condition was stable with a follow-up of 12 months.

Vision loss in Neurology was usually associated with ON or NMO. NMO can be associated with other autoimmune disease, such as T1DM [14]. So it is necessary to differentiate WS from NMO with T1DM in children.

Based on the findings of the present case, we should be aware of WS in adolescence patients presenting with T1DM (non-autoimmune) and OA without any signs of diabetic retinopathy. And it is mandatory to perform direct sequencing analysis of the WFS1 gene to confirm
the clinical diagnosis. No genotype-phenotype correlation has been identified [6]. Although our study increases the spectrum of WFS1 gene mutations with a novel variant c.1760G > A, whether the novel mutation relates with mild clinical symptoms or just involves vision and blood glucose remains to be further studied and confirmed.

Abbreviations
ANA: Anti-nuclear antibody; ANCA: Anti-neutrophil cytoplasmic antibodies; AQP4: Aquaporin 4; D: Deafness; Dm: Diabetes mellitus; ENA: Extracted nuclear antigens; ER: Endoplasmic reticulum; HbAc: Glycosylated hemoglobin; HGMD: Human Gene Mutation Database; MRI: Magnetic resonance image; NMO: Neuromyelitis optica; OA: Optic atrophy; OCB: Oligoclonal bands; OCT: Optic coherence tomography; OH: Optic neuritis; TSH: Thyroid stimulating hormone; VEP: Visual evoked potential; WFS1: Wolfram syndrome 1; WS: Wolfram syndrome

Acknowledgments
The authors would like to thank the patient’s family for their participation and help.

Funding
This study was supported by National Science Foundation of Guangdong Province (No. 2015A030313167), Science & Technology Project of Guangzhou (No. 201510010251) and National Science Foundation of China (No. 81271327).

Availability of data and materials
The data and materials used during the current study are available from the first author on reasonable request.

Authors’ contributions
ML and JL conceived the study and revised the manuscript critically for intellectual content. HY and LX collected the raw data from our hospital work system and critically reviewed the manuscript. ML and JL interpreted the results for the case report, drafted, wrote and revised the report, and provided important intellectual review. XZ and FP analysed the data and reviewed the manuscript. All authors have read and approved the final manuscript.

Ethics approval and consent to participate
This research was approved by the Ethics Committee of the Third Affiliated Hospital of Sun Yat-Sen University (200733). Written informed consent was obtained from the patient for the publication.

Consent for publication
Written informed consent was obtained from the parent for the publication of this case report.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 18 May 2017 Accepted: 7 March 2018
Published online: 17 March 2018

References
1. Barrett TG, Bundey SE, Macleod AF. Neurodegeneration and diabetes: UK nationwide study of Wolfram (DIDMOAD) syndrome. Lancet. 1995;346:1458-63.
2. Marshall BA, Perrett MA, Paciorkowski AR, Hoekel J, Karzon R, Wasson J, et al. Phenotypic characteristics of early Wolfram syndrome. Orphanet J Rare Dis. 2013;8:64. https://doi.org/10.1186/1750-1172-8-64.
3. Chaussenot A, Bannwarth S, Rouzier C, Viallettes B, Mladern SA, Chabrol B, et al. Neurologic features and genotype-phenotype correlation in Wolfram syndrome. Ann Neurol. 2011;69:501-8. https://doi.org/10.1002/ana.22160.
4. Rigoli L, Di Bella C. Wolfram syndrome 1 and Wolfram syndrome 2. Curr Opin Pediatr. 2012;24:512–7. https://doi.org/10.1097/MOP.0b013e328354cdcf.
5. Takeda K, Inoue H, Tanizawa Y, Matsuaki Y, Oba J, Watanabe Y, et al. Wfs1 (Wolfram syndrome 1) gene product: predominant subcellular localization to endoplasmic reticulum in cultured cells and neuronal expression in rat brain. Hum Mol Genet. 2001;10:71-84.
6. Rigoli L, Lombardo F, Di Bella C. Wolfram syndrome and WFS1 gene. Clin Genet. 2011;79:103–17. https://doi.org/10.1111/j.1399-0004.2010.01522.x.
7. Zmyslowska A, Borowiec M, Fichna P, Iwaniszewska B, Majkowska L, Pietrzak J, et al. Delayed recognition of Wolfram syndrome frequently misdiagnosed as type 1 diabetes with early chronic complications. Exp Clin Endocrinol Diabetes. 2014;122:35-8. https://doi.org/10.1055/s-0033-1357160.
8. Pennings RJ, Huygen PL, van den Ouweland JM, Cynx K, Diikkeschei LD, Van Camp G, et al. Sex-related hearing impairment in Wolfram syndrome patients identified by inactivating WFS1 mutations. Audiol Neurootolo. 2004;9:51-62. https://doi.org/10.1159/000074187.
9. Plantinga RF, Pennings RJ, Huygen PL, Bruno R, Eller P, Barrett TG, et al. Hearing impairment in genotyped Wolfram syndrome patients. Ann Otol Rhinol Laryngol. 2008;117:494–500. https://doi.org/10.1177/00034890811700704.
10. Barrett TG, Bundey SE. Wolfram (DIDMOAD) syndrome. J Med Genet. 1997;34:838–41.
11. Ribeiro MR, Crispim F, Vendramini MF, Mosiles RS. Wolfram syndrome: from definition to molecular bases. Anq Bras Endocrinol Metabolob. 2006;50:839–44.
12. Fonseca SG, Ishigaki S, Oslowski CM, Lu S, Lipson KL, Ghosh P, et al. Wolfram syndrome 1 gene negatively regulates ER stress signalling in rodent and human cells. J Clin Invest. 2010;120:744–55. https://doi.org/10.1172/JCI39678.
13. Yamamoto H, Hofmann S, Hamasaki DI, Yamamoto H, Kreczmanski P, Schmitz C, et al. Wolfram syndrome 1 (WFS1) protein expression in retinal ganglion cells and optic nerve glia of the cynomolgus monkey. Exp Eye Res. 2006;83:1303–6. https://doi.org/10.1016/j.exer.2006.06.010.
14. Kawazoe T, Araki M, Lin Y, Ogawa M, Okamoto T, Yamamura T, et al. New-onset type I diabetes mellitus and anti-aquaporin-4 antibody positive optic neuritis associated with type I interferon therapy for chronic hepatitis C. Intern Med. 2012;51:2625–9. https://doi.org/10.2169/internalmedicine.51.7771.